the Survival of critically ill patients with COVID-19 pneumonia-a single-center experience

• DOI: 10.3855/jidc.16650
• Publication Date: 2022-10-12T19:22:00Z
• Authors: Marina Stojanović; Biljana Miličić; Nemanja Purić; Jelena Jeremić; Marko Jović; Milan Stojčić; Maja Omčikus; Nikola Trboljevac; Jelena Velickovic
• Keywords: Tocilizumab; Single Center

The aim of the study was to determine survival probability critically ill patients with COVID-19 infection who needed mechanical ventilation and efficacy Tocilizumab use.The designed as a retrospective analysis consecutive older than 18 years, treated in an intensive care unit. criteria for admission unit severe respiratory failure requiring ventilation. All received corticosteroid therapy (methylprednisolone 1-2 mg/kg). used at dose 8 mg/kg form disease (onset, or developed ARDS), followed by cytokine storm (IL-6 ≥ 40 ng/L CRP 50 mg/L).88 were included study. Intrahospital mortality 48.86%. No statistically significant difference observed between without tocilizumab therapy. In group whom this applied, values intrahospital 45.7%, while only 0.93%. noninvasive (NIV) 94.7%, invasive (IMV) 0.78%. duration symptoms before hospitalization (RR-1.088 CI 1.025-1.155, p < 0.05), well IMV (RR-0.906 0.841-0.976, shown be independent predictor poor outcome.The most caused remains high. Independent predictors outcomes late initiation appropriate